TrialBritish journal of haematology2010

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Pierre Fenaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.